[4][3] It is generally accepted that removing the hydroxy group from the phenol structure of any classical cannabinoid benzopyran (such as THC) results in dramatically less CB1 activity and heightened CB2 activity.

[citation needed] JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's disease, in addition to preventing cognitive impairment and loss of neuronal markers.

Additionally, cannabinoids at this receptor completely abolish neurotoxicity related to microglia activation in rat models.

[citation needed] It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid.

[5] JWH-133 is not specifically listed in the United States controlled substance act but may be considered an analog of THC (under the Federal Analogue Act) if sold for human consumption.